Pharma MNCs increase focus on Indian market: ICRA
News | 20 June 2012
The aggressive healthcare budget cuts could hurt pricing for generic players. It is feared that transformation of German market from being a branded generics to ...
Click on the link to read the full article at Times of India
(This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
